Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224


ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity.

Rong JX, Blachford C, Feig JE, Bander I, Mayne J, Kusunoki J, Miller C, Davis M, Wilson M, Dehn S, Thorp E, Tabas I, Taubman MB, Rudel LL, Fisher EA.

Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):4-12. doi: 10.1161/ATVBAHA.112.252056. Epub 2012 Nov 8.


Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice.

Kusunoki J, Hansoty DK, Aragane K, Fallon JT, Badimon JJ, Fisher EA.

Circulation. 2001 May 29;103(21):2604-9.


Acyl-coenzymeA (CoA):cholesterol acyltransferase inhibition in rat and human aortic smooth muscle cells is nontoxic and retards foam cell formation.

Rong JX, Kusunoki J, Oelkers P, Sturley SL, Fisher EA.

Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):122-7. Epub 2004 Oct 21.


Inhibition of Orai1 Store-Operated Calcium Channel Prevents Foam Cell Formation and Atherosclerosis.

Liang SJ, Zeng DY, Mai XY, Shang JY, Wu QQ, Yuan JN, Yu BX, Zhou P, Zhang FR, Liu YY, Lv XF, Liu J, Ou JS, Qian JS, Zhou JG.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):618-28. doi: 10.1161/ATVBAHA.116.307344. Epub 2016 Feb 25.


Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.

Rahtu-Korpela L, Määttä J, Dimova EY, Hörkkö S, Gylling H, Walkinshaw G, Hakkola J, Kivirikko KI, Myllyharju J, Serpi R, Koivunen P.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):608-17. doi: 10.1161/ATVBAHA.115.307136. Epub 2016 Feb 4.


Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice.

Nagashima M, Watanabe T, Shiraishi Y, Morita R, Terasaki M, Arita S, Hongo S, Sato K, Shichiri M, Miyazaki A, Hirano T.

Atherosclerosis. 2010 Sep;212(1):70-7. doi: 10.1016/j.atherosclerosis.2010.04.027. Epub 2010 May 4.


Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability.

Hans CP, Zerfaoui M, Naura AS, Catling A, Boulares AH.

Cardiovasc Res. 2008 Jun 1;78(3):429-39. doi: 10.1093/cvr/cvn018. Epub 2008 Jan 31.


Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.

Chen Y, Duan Y, Yang X, Sun L, Liu M, Wang Q, Ma X, Zhang W, Li X, Hu W, Miao RQ, Xiang R, Hajjar DP, Han J.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):948-59. doi: 10.1161/ATVBAHA.114.305116. Epub 2015 Feb 19.


Insulin-Like Growth Factor-1 Receptor Deficiency in Macrophages Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Apolipoprotein E-Deficient Mice.

Higashi Y, Sukhanov S, Shai SY, Danchuk S, Tang R, Snarski P, Li Z, Lobelle-Rich P, Wang M, Wang D, Yu H, Korthuis R, Delafontaine P.

Circulation. 2016 Jun 7;133(23):2263-78. doi: 10.1161/CIRCULATIONAHA.116.021805. Epub 2016 May 6.


Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice.

Lenglet S, Thomas A, Soehnlein O, Montecucco F, Burger F, Pelli G, Galan K, Cravatt B, Staub C, Steffens S.

Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):215-23. doi: 10.1161/ATVBAHA.112.300275. Epub 2012 Dec 13.


Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregulation of ATP-binding cassette transporter A1.

Lv YC, Yang J, Yao F, Xie W, Tang YY, Ouyang XP, He PP, Tan YL, Li L, Zhang M, Liu D, Cayabyab FS, Zheng XL, Tang CK.

Atherosclerosis. 2015 May;240(1):80-9. doi: 10.1016/j.atherosclerosis.2015.02.044. Epub 2015 Feb 24.


Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis.

Perrey S, Legendre C, Matsuura A, Guffroy C, Binet J, Ohbayashi S, Tanaka T, Ortuno JC, Matsukura T, Laugel T, Padovani P, Bellamy F, Edgar AD.

Atherosclerosis. 2001 Apr;155(2):359-70.


NaoXinTong Inhibits the Advanced Atherosclerosis and Enhances the Plaque Stability in Apolipoprotein E Deficient Mice.

Yang X, Sun L, Li Y, Ma C, Yang J, Zhang W, Zhao B, Jia L, Duan Y, Han J, Li X, Chen Y.

J Cardiovasc Pharmacol. 2016 Mar;67(3):203-11. doi: 10.1097/FJC.0000000000000334.


Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice.

Li G, Wu XW, Lu WH, Ai R, Chen F, Tang ZZ.

BMC Cardiovasc Disord. 2014 Oct 18;14:145. doi: 10.1186/1471-2261-14-145.


Hydrogen decreases athero-susceptibility in apolipoprotein B-containing lipoproteins and aorta of apolipoprotein E knockout mice.

Song G, Tian H, Qin S, Sun X, Yao S, Zong C, Luo Y, Liu J, Yu Y, Sang H, Wang X.

Atherosclerosis. 2012 Mar;221(1):55-65. doi: 10.1016/j.atherosclerosis.2011.11.043. Epub 2011 Dec 13.


Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice.

Rasmiena AA, Barlow CK, Stefanovic N, Huynh K, Tan R, Sharma A, Tull D, de Haan JB, Meikle PJ.

Atherosclerosis. 2015 Dec;243(2):598-608. doi: 10.1016/j.atherosclerosis.2015.10.096. Epub 2015 Oct 26.


Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.

Hurt-Camejo E, Gautier T, Rosengren B, Dikkers A, Behrendt M, Grass DS, Rader DJ, Tietge UJ.

Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2707-14. doi: 10.1161/ATVBAHA.113.301410. Epub 2013 Oct 10.


The nitroxide radical TEMPOL prevents obesity, hyperlipidaemia, elevation of inflammatory cytokines, and modulates atherosclerotic plaque composition in apoE-/- mice.

Kim CH, Mitchell JB, Bursill CA, Sowers AL, Thetford A, Cook JA, van Reyk DM, Davies MJ.

Atherosclerosis. 2015 May;240(1):234-41. doi: 10.1016/j.atherosclerosis.2015.03.012. Epub 2015 Mar 16.


Supplemental Content

Support Center